Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 22

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
est expense recognized during that quarter.

Other Income

For the three months ended
December 31 2024, the Company reported a net other expense of $(454,007), a substantial increase from the net other expense of $(22,151),
in 2023. The increase was primarily driven by the recognition of a Derivative Loss of $(416,016) in 2024. For the quarter ended December
31, 2024 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2023.

  22  

Net Loss

The Company recognized an
Operating Loss of $ 61,378 during the three months ended December 31, 2024 whereas the Company recognized an Operating Loss of $ 122,782
for the same period ended 2023. The reduction in operating loss is primarily attributable to a reduction in Consulting and Professional
Fees and Research and Development expenses incurred during the period ended 2024 as compared to the quarter ended in 2023.

Net Loss is $ 515,384 for
the three months ended December 31, 2024 as opposed to a Net Loss of $144,933 for the same period ended 2023 the difference primarily
attributable to the recognition by the Company of Derivative Loss of $ 416,016 during the three months ended December 31, 2024.

Working Capital

                           December 31, 2024                      September 30, 2024                  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────
  Current assets           $                         173,683      $                          143,351  
  Current liabilities                              5,870,459                               5,378,456  
  Working capital          $                      (5,696,776      $                       (5,235,105  

Working capital deficit increased
by $ 461,670 from September 30, 2024 to December 31, 2024, primarily due to increase in Derivative Liability.

Liquidity and Capital
Resources

                                                            Quarter Ended                                       
                                                            December 31,                                        
                                                            2024                            2023                
  Net cash used in operating activities                     $                  (66,379      $         (162,336  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net cash provided by financing activities                                     65,799                 165,797  
  Net increase (decrease) in cash and cash